New drug targets hidden heart risk in early trial

NCT ID NCT03626662

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This early-stage study tested a new medicine called AMG 890 in 79 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease. The goal was to check the drug's safety and how the body processes it. Participants received a single dose of the drug or a placebo, and researchers monitored side effects and drug levels in the blood.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clinical Medical and Analytical eXellence CMAX

    Adelaide, South Australia, 5000, Australia

  • Excel Medical Clinical Trials

    Boca Raton, Florida, 33434, United States

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida, 32216, United States

  • Linear Clinical Research Limited

    Nedlands, Western Australia, 6009, Australia

  • Medpace Inc

    Cincinnati, Ohio, 45227, United States

  • New York University

    New York, New York, 10016, United States

  • Orange County Research Center

    Tustin, California, 92780, United States

  • QPS Miami Research Associates

    South Miami, Florida, 33143, United States

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States

Conditions

Explore the condition pages connected to this study.